Exploring *Leishmania*-Host Interaction with Reactome, a Database of Biological Pathways and Processes

Julieth Murillo^{1,2}, Bijay Jassal³, Maria Adelaida Gómez^{1,4#}, Henning Hermjakob^{5#}

¹ CIDEIM - Centro Internacional de Entrenamiento e Investigaciones Médicas, Cali, Colombia

² Pontificia Universidad Javeriana, Cali, Colombia

³ Ontario Institute for Cancer Research, Toronto, Canada.

⁴ Universidad Icesi, Cali, Colombia

⁵ European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK.

Running title: *Leishmania* infection in Reactome

Keywords: *Leishmania*, Reactome, pathway, ORA, enrichment

Address correspondence

Henning Hermjakob, hhe@ebi.ac.uk

Maria Adelaida Gómez, mgomez@cideim.org.co

Abstract

Leishmaniasis is a parasitic disease with a wide range of clinical manifestations. Multiple aspects of the *Leishmania*-host interaction, such as genetic factors and modulation of microbicidal functions in host cells, influence pathogenesis, disease severity and treatment outcome. How do scientists contend with this complexity? Here, we work towards representing detailed, contextual knowledge on *Leishmania*-host interactions in the Reactome pathway database to facilitate the extraction of novel mechanistic insights from existing datasets. The Reactome database uses a hierarchy of abstractions that allows for

the incorporation of detailed contextual knowledge on biological processes matched to differentially expressed genes. It also includes tools for enhanced over-representation analysis that exploits this extra information. We conducted a systematic curation of published studies documenting different aspects of the *Leishmania*-host interaction. The “*Leishmania* infection pathway” included four sub-pathways: phagocytosis, killing mechanisms, cell recruitment, and *Leishmania* parasite growth and survival. As proof-of-principle of the usefulness of the released pathway, we used it to analyze two previously released transcriptomic datasets of human and murine macrophages infected with *Leishmania*. Our results provide insights on the participation of ADORA2B signaling pathway in the modulation of IL10 and IL6 in infected macrophages. This work opens the way for other researchers to contribute to, and make use of, the Reactome database.

Importance

Leishmaniasis is a neglected disease infectious disease which affects more than 1.5 million people annually. Many researchers in the field apply -omic technologies to dissect the basis of clinical and therapeutic outcomes and access drug targetable features in the host-parasite interaction, among others. However, getting mechanistic insights from -omics data to such end is not an easy task. The most common approach is to use the -omics data to inquire pathways databases. The retrieved list of pathways often contains vague names that lack the biological context. In this study, we worked to create the *Leishmania* infection pathway in the Reactome database. With two practical examples from transcriptomics and microarray data, we demonstrated how this pathway facilitates the analysis of such data. In both datasets, we found a common mechanism of IL10 and IL6 production that the authors did not advert in their previous analysis, providing proof-of-principle of the tool’s enhanced potential for knowledge extraction. *Leishmania* infection pathway is in its first version, and must be expanded to cover the current knowledge base of the *Leishmania*-host interaction. We strongly encourage contributions from domain experts for the completion of *Leishmania* infection pathways.

Introduction

The interaction between a parasite and its host is a fight for dominance. Who wins? How does disease progress? A multitude of factors determine the course of infection. These depend upon both the status of the host and the parasite. Omics data shed light on the multitude of activated mechanisms within the host-parasite interactome, by providing long lists of differentially expressed (DE) molecules. However, such data is a means for generating knowledge, not an end. The ultimate goal is to interpret this data to build a mechanistic understanding of the interactions at hand. This exercise is made tractable by the existence of pathway databases that curate and organize current knowledge (1–3). Typically, the databases are used to find known biological processes that could underlie the data. A common methodology is Over-Representation Analysis (ORA). This takes the set of DE genes from the data, and iteratively compares them to the set of genes involved in each separate pathway in the database. It uses the overlap between these two sets to predict the statistical likelihood of the biological pathway being represented in the data (4). Mechanistic hypotheses on the processes underlying the data are then proposed by the researcher, based on the ORA results.

Biological process labels within a database often lack context (e.g. ‘immune system’). Does the process occur within one particular cell type, or more? Across species? In a diseased organism? In the context of a pathogen-host interaction? It is difficult to build detailed hypotheses from such labels using ORA, or indeed other analytical approaches.

The Reactome database builds a hierarchy of abstractions into which the observed features of any biological process can be incorporated. At the top level of the hierarchy, high level characteristics are represented: Is it a disease? Is it infectious or metabolic? At lower levels, features such as specific, temporally-ordered sequences of cellular processes are represented (3). Choices such as how many levels of abstraction to include, and what each should represent, depend to some extent upon the expertise of the curator. Therefore, it is critical that the curator has expert domain knowledge or that they collaborate with an appropriate expert in the field.

The purpose of this work was to add representative features and variability of the *Leishmania* spp.-host interaction into the Reactome database. In the terminology of the database, this representation is known as a ‘pathway’. Our pathway is sufficiently flexible

as to allow for expansion and revision as new results are published. It incorporates detailed information on biological processes known to be activated during the *Leishmania*-host interaction. In particular, we focused on those processes correlated with the outcome of infection.

We explicitly demonstrate the utility of our database curation. We took two existing datasets to which ORA or manual revision of the literature was previously applied. With our expanded database, we uncover new mechanistic insights. In the long term, we hope that the research community will be able to use our pathways as a source of primary consultation, and as a curated database for functional and mechanistic interpretation of new data derived from -omics technologies, functional tests, or *in-silico* experiments. We believe that this pathway will enable fast and curated access to the integrative mechanisms of importance in leishmaniasis.

Results

Abstracting the top-level pathway: phagocytosis, killing mechanisms, cell recruitment and responses favoring *Leishmania* parasites.

The curation of a pathway in Reactome starts by structuring pathways into hierarchical sections. The parent *Leishmania* infection pathway was structured into four subpathways describing the major processes involved: phagocytosis, killing mechanisms, cell recruitment and *Leishmania* parasite growth and survival. For each subpathway, there is extensive literature on the specific host responses to *Leishmania* infection, and their implication in the outcome of infection (5–7).

Leishmania parasites are transmitted to the host through the bite of a sand-fly that injects the motile promastigote form into the dermis of humans and other warm-blooded animals. Therein, the parasite interacts with the host cell(s) to establish the intracellular niche, where it will adopt the amastigote form (8). Paradoxically, macrophages, professional phagocytes of the innate immune system, are the main host cells for *Leishmania*. The first interaction of the parasite with the host cell is crucial to the outcome of the infection (5). The type of phagocytic receptor or pattern recognition receptor stimulated might influence

the signaling cascade(s) that will trigger or inhibit cellular mechanisms involved in parasite killing or permissiveness for infection. Deregulated immune responses contribute to pathology (9). Pro and anti-inflammatory mediators must be expressed at the “right” time and in the “appropriate” magnitude, in order to have a healing response (9). This discussion motivates our abstraction of existing knowledge into the categories of phagocytosis, killing mechanisms, cell recruitment (pro-inflammatory response), and *Leishmania* parasite growth and survival (figure 1).

Figure 1: Textbook-style diagram representing the top-level pathway “*Leishmania* infection”. The major steps occurring in the dermis were compartmentalized into four categories: phagocytosis, killing mechanisms, cell recruitment, and *Leishmania* parasite growth and survival. On the webpage (<https://reactome.org/PathwayBrowser/#/R-HSA-9658195>), the magenta rectangular labels are interactive and take the user to the content of each subpathway.

***Leishmania* infection pathways: From a sketch on paper to Reactome database.**

Reactome’s curation tool is a graphical user interface (GUI), that connects to its central database with which new information can be added to existing or new pathways. We started with a sketch of the overall pathways we wanted to curate for the first version of the “*Leishmania* infection pathway”. Then, we identified what molecules/entities and reactions already existed in the database and which ones needed to be added. Similarly, we accounted

for the molecular interactions that were already described in existing Reactome pathways. If new reactions were required, they were created from scratch, supported by literature references. Table 1 summarizes these metrics.

Table 1: Curation and annotation metrics for the creation of *Leishmania* infection pathways in Reactome.

Pathway	Entities		Reactions/Catalysis/Regulation		New literature references
	New	Re-used	New	Re-used	
Phagocytosis	9	141	12	14	7
Killing mechanisms	5	18	9	0	8
Cell recruitment	3	28	3	24	9
<i>Leishmania</i> parasite growth and survival	15	51	19	12	17
Total	32	238	42	50	41

Structuring the lowest-level pathways: signaling cascades traceable from a membrane protein to the production of effector molecules.

As part of the host response against *Leishmania*, many signaling cascades are modulated (activated or inactivated). Once a cellular/membrane receptor is stimulated, the downstream signal transduction can result in the activation of many molecules with different effects in the system (e.g. interleukins inducing the polarization of several types of T-cells, or chemokines mediating the recruitment of immune cells to different tissues, among others). That is why general pathway labelling such as “TNF-signaling”, might not be informative enough, and can allow for erroneous biological interpretations if the gene lists contained within enriched pathways are not carefully analysed. There could be many regulatory processes that favor one direction rather than another in a specific signaling pathway (as it can be noticed in TNF-pathway in Reactome, R-HSA-75893 <https://reactome.org/PathwayBrowser/#/R-HSA-75893> and KEGG, hsa04668-https://www.genome.jp/kegg-bin/show_pathway?hsa04668). Therefore, we structured the lowest-level pathways in each of four subpathways, starting off from an activated membrane protein (e.g., receptors, ion channels or enzymes). This was followed by inclusion of signalling and accessory molecules and finished with synthesis of effector

molecules that are consistent with the overall biological processes underlying the subpathway (e.g., reactive oxygen species –ROS- for “killing mechanisms”).

For this first version of the *Leishmania* infection pathway, we chose the membrane proteins FCGR3A, FZD7, P2RX4, P2RX7, ADORA2B, and CD163 and their downstream signaling cascades. Although additional membrane molecules are known to participate in the initial macrophage-*Leishmania* interaction, such as complement receptors, toll-like receptors - TLRs-, or chemokine receptors among others (10–12), we selected less “classical” membrane molecules to increase the breath of mechanistic interpretation of host-*Leishmania* –omic datasets. Shown in figure 2 are the structures of the four subpathways, each of which contains a set of reactions. Supporting references evidencing their relevance in the context of leishmaniasis will be discussed below.

Figure 2: Hierarchical structure of the *Leishmania* infection pathway showing the four subpathways and their contents. Each indentation introduces a new subpathway; as an example, “parasite infection” is the parent pathway for the subpathway “*Leishmania* phagocytosis”, which, to date only contains *FCGR3A*-mediated phagocytosis.

I. Parasite Infection/*Leishmania* phagocytosis: The phagocytosis subpathway was built to account for the different types of phagocytic receptors that *Leishmania* parasites can utilize for their entry into host cells. We started by

adding FCGR3A-mediated phagocytosis. To build it, we referenced the pre-existing Reactome pathway “FcG receptor (FCGR) dependent phagocytosis” (<https://reactome.org/content/detail/R-HSA-2029480>). Overall, 14 reactions were re-used from this pathway while 12 new reactions were created to represent phagocytosis in the context of *Leishmania* infection (table 1). The starting point was the binding of immunoglobulin G antibodies (IgG) to either an unknown *Leishmania* amastigote (abbreviate as: Lma) surface molecule or the glycoinositol phospholipid - GIPL (13, 14), as shown in figure 3a. These interactions correspond to binding reaction types in Reactome, with the product of binding being a complex comprising the inputs. The complexes “IgG:Lma surface” and “IgG:GIPL” represent the opsonization of the *Leishmania* amastigote by the antibody IgG, during a “second round” of host-parasite contact where the proliferative form and infective form in the host is the amastigote. We assumed the same course when opsonization occurs via these known, or other unknown molecules. Therefore, we collated the two complexes into one entity, which in Reactome is represented by the defined set “IgG:Lma antigens”. From here, downstream reactions continue towards the activation of actin filaments that then continue to the formation of the phagocytic cup. The overall diagram depicting each step of the pathway can be accessed through this link <https://reactome.org/PathwayBrowser/#/R-HSA-9664422&PATH=R-HSA-1643685,R-HSA-5663205,R-HSA-9658195,R-HSA-9664407,R-HSA-9664417>. A close-up depicting a portion of the pathway is found in figure 3A.

The route of entry into the macrophage can affect the fate of *Leishmania* parasites (5). We expect to incorporate the internalization processes that are mediated by other receptors into the *Leishmania* phagocytosis subpathway. This includes complement receptors (CR3 and CR1), mannose receptor-MR, and fibronectin receptors-FNRs (5). Similarly, the “Parasite infection” subpathway will be populated with the steps that describe the maturation of the phagocytic cup, and so on.

II. **Killing mechanisms:** this subpathway was designed to contain the signaling cascades that converge in the production of antimicrobial molecules in the context of leishmaniasis. We started by curating the activation of the receptor Frizzled-7 (FZD7) by the ligand WNT5 and its downstream cascade. To build this pathway we reviewed publications that contain the original experimental data used to determine the reactions details (15–19). WNT5 is known for being a highly specific regulated gene in response to microbial infection (20–22) including leishmaniasis (23), where it seems to be involved in mechanisms that dampen the parasite load within the macrophage. Complementary, FZD7 acts as a receptor of WNT5 which, upon binding, is implicated in the initiation of the non-canonical WNT pathway that leads to re-organization of the cytoskeleton to allow a process called planar cell polarity (PCP) (22). The activation of the WNT5:FZD7 non-canonical signaling cascade that drives PCP is being studied for its involvement in inflammatory responses (24). Treatment of RAW264.7 macrophages with recombinant WNT5 induced NADPH oxidase-mediated ROS production, which has been suggested to contribute to the macrophage control of *L. donovani*. Consequently, detailed understanding of how the WNT signaling network defines host responses to infection could be important to identify new potential therapeutic targets (22).

We represented in 9 reactions, the activation of FZD7 by the WNT5 ligand, resulting in the production of ROS (table 1). Unlike the phagocytosis pathway, these reactions correspond to a host's response to the infection, even if no parasite components are depicted in the diagram (found at <https://reactome.org/PathwayBrowser/#/R-HSA-9673324&PATH=R-HSA-1643685,R-HSA-5663205,R-HSA-9658195,R-HSA-9664420>). In future versions we will incorporate the cross talk with signaling cascades, like TLR-signaling, that activate antimicrobial functions and synthesis of antimicrobial molecules.

III. **Cell recruitment:** this subpathway was aimed at bringing together signaling pathways that converge in the induction of gene expression and synthesis of

chemokines and pro-inflammatory cytokines. It is known that a proinflammatory response early in the infection enhances host cell microbicidal mechanisms (25). However, the recruitment of inflammatory cells to the site of infection, once the parasite load has been controlled, transforms the course of infection and can lead to immunopathology (9). Therefore, it is important to curate and represent specific pathways that have shown to be activated upon *Leishmania* infection, resulting in the production of pro-inflammatory mediators.

The first specific mechanism we curated was the activation of the purinergic receptors P2RX4 and P2RX7. The liberation of ATP normally occurs in tissues facing stressful stimuli such as infection (26). Binding of ATP to purinergic receptor activates the inflammasome leading to subsequent activation of interleukin 1 beta-IL1 β , which promotes the recruitment and activation of macrophages (27). We represented this process in 27 reactions (table 1), that included a regulatory step mediated by NTPDase1 and NTPDase5, which reduces ATP to adenosine (28). The molecular diagram can be found at <https://reactome.org/PathwayBrowser/#/R-HSA-9664424&SEL=R-HSA-9660826&PATH=R-HSA-1643685,R-HSA-5663205,R-HSA-9658195>.

There are many other pathways promoting cell recruitment as a response to *Leishmania* infection with different consequences for the parasite and the host (29). In future expansions of this subpathway, it would be possible to highlight cross talk between different cascades that target the same effector molecules.

IV. *Leishmania* parasite growth and survival: this subpathway covers the host responses that favor intracellular parasite survival, and the mechanisms used by the parasite to hijack host cell functions. To survive as an intracellular parasite, *Leishmania* evades the activation of host cell microbicidal machineries. Many mechanisms facilitate this purpose. On the host side, the production of anti-inflammatory mediators often occurs alongside the repression of expression of

antimicrobial molecules, together with the recruitment of regulatory immune cells (e.g., regulatory T-cells). From the parasite side, inactivation of host molecules through mechanisms such as cleavage or activation of phosphatases are part of its repertoire (9). Induction of anti-inflammatory molecules was the first mechanism that we curated, compiling the steps that describe the cleavage of the membrane protein CD163, the activation of the receptors FCGR3A and ADORA2B, and ending with the corresponding production of the known anti-inflammatory molecules sCD163, IL4, and IL10, as well as the dual functioning IL6.

Macrophages infected with *L. amazonensis* or *L. donovani* strongly express the membrane protein CD163 (30–32), and soluble CD163 (sCD163) has been proposed as biomarker of visceral leishmaniasis. The hypothesis of the association between sCD63 and an anti-inflammation status is that it interferes with the proliferation of T-cells (33, 34). sCD163 is formed from the increased shedding of CD163 mediated by the metalloprotease ADAM17 (35, 36). Posteriorly, it might translocate to the cytoplasm of T-cells (through an unknown mechanism) where it binds with a protein involved in the proliferation process (33, 34). In “CD163 mediated anti-inflammatory responses” we represented, in 9 reactions, the production of sCD163 including the steps that precede the activation of ADAM17. Additionally, we included the positive regulation of glucocorticoids, IL6 and IL10 on CD163 gene expression (37–40). In figure 3B we show the molecular diagram depicting the pathway.

IL-10 is an important immunoregulatory cytokine produced by many cell populations; in macrophages it is induced after the stimulation of TLRs, FCG receptors or by TLR-FCGR crosstalk (41). Classically, its function is considered to be the limitation and termination of inflammatory responses and the regulation of differentiation of several immune cells (42). In the context of leishmaniasis, IgG-opsonized amastigotes have been shown to induce IL10 production through FCGRs, which in turn suppresses the killing mechanisms in

phagocytic cells (14). We represented, in 21 steps, the activation of FCGR3A that leads to the activation of the transcription factor CREB1, ending with the production of IL10.

Finally, we curated ADORA2B-mediated anti-inflammatory responses. ADORA2B is a receptor for the ribonucleoside adenosine. Its activation leads to the production of anti-inflammatory cytokines which have been shown to favor *Leishmania* infection and survival (43–45). Apparently, this pathway exerts an opposing/regulatory response to the purinergic signaling pathway. The blockade in the production of pro-inflammatory cytokines may come with the inhibition of killing mechanisms (46). We represented this pathway with 6 reactions, starting with the binding of adenosine to ADORA2B, and ending with synthesis of IL6. Both FCGR3A and ADORA2B signaling pathways activate transcription factors, generating a positive feedback loop for transcription of more anti-inflammatory cytokines (47, 48). In future versions, these reactions might be incorporated, as well as other pathways leading to the synthesis of other anti-inflammatory mediators known to be induced during the *Leishmania*-host interactions. Moreover, other mechanisms that favor the persistence of *Leishmania* parasites must be added into new subpathways (e.g., Polyamine synthesis). The representation of these pathways in Reactome is available in the following link: <https://reactome.org/PathwayBrowser/#/R-HSA-9662851&PATH=R-HSA-1643685,R-HSA-5663205,R-HSA-9658195,R-HSA-9664433>.

326 A.

arrangement of the entities in the reactions can be easily followed on the web page, by clicking on the arrows that connect adjacent steps.

***Leishmania* infection pathways enhancing transcriptome data analysis**

The first version of *Leishmania* infection pathways was released in March 2020. All released data can make use of Reactome pathway analysis tools. We used the ORA tool to test the impact of context-dependent labels on published datasets (prior march-2020) that explored the *Leishmania*-host interaction.

In 2015, Dillon *et al.* (49) explored the early response of macrophages to infection with *L. major*, using RNA-seq. With the differentially expressed (DE) gene list (>|2|-fold, uninfected macrophages versus infected macrophages at 4 hours post-infection), they performed ORA against the curated pathways in the KEGG database. For the up-regulated genes, the results included cytokine-cytokine receptor interactions, TNF-signaling pathway and NFkappa B-signaling pathway, among other pathways. An overall interpretation of these enriched pathways may suggest that the early infection of macrophages by *L. major* leads to induction of pro-inflammatory responses; as an example, TNF-signalling as represented in KEGG (PATHWAY: hsa04668), classically leads to the recruitment of inflammatory cells. However, transduction of the signal may induce the activation of factors that contribute to opposite responses, such as tissue regeneration (with VEGF and EDN1) (50, 51). Interestingly, among their gene-specific analyses, Dillon *et al.* identified a set of genes involved in anti-inflammatory responses (*Csf1*, *Csf3*, *Il10*, *Il11r*, *Il1rn*, *Socs3*, *Hmox1*, *Egfr* and, *Vegf*). However, the mechanisms that lead to production of these effector molecules, or how they contribute to achieve or maintain the underlying immune status couldn't be inferred from the KEGG pathway analysis. To overcome this gap, we implemented ORA from the same DE gene list (supplementary table S1) in Reactome. Among enriched pathways (table S1), were some of the *Leishmania* infection subpathways. As reported by Dillon and colleagues, FCGR3A subpathway (figure 4A) was found downregulated. Interestingly, the most over-represented pathway was the ADORA2B mediated anti-inflammatory cytokine production (Fold change-FC = 3.25). This pathway contributes to the expression of IL6 (FC = 7.68) and IL10 (FC = 17.05), through the

activation of the transcription factor CREB (FC = 2.75) (figure 4B). This pathway, simultaneously, leads to the activation of killing mechanisms, as well as to the production of IL10. Neither authors nor we found pathways involved in the former. Therefore, this suggests an alternative mechanism mediated by ADORA2B, that leads to production of IL10, and does not induce parallel pro-inflammatory consequences or the activation of antimicrobial molecules.

Complementary, we analyzed the microarray data from Gregory *et al.* (52) which represents the transcriptomic response of murine macrophages to infection with *L. major* and *L. donovani*. The authors stated that there were few differences in the number of genes and the magnitude of the expression with both species. Like Dillon's dataset, the ADORA2B subpathway was enriched among upregulated genes (figure 4C and supplementary table S2). These results highlight the identification of ADORA2B-pathway driving anti-inflammatory cytokine production, consistently activated in macrophages infected with different *Leishmania* species. These results substantiate the usefulness of the *Leishmania* infection pathways for gaining mechanistic insights from new and previously published data. In expanded versions of this pathway, secondary analyses like the one we performed, would shed light on response patterns against the infection with different *Leishmania* species, as well as species-dependent responses.

A.

386 B.

387 C.

388 Figure 4: Results of applying ORA in Reactome, on the datasets generated by Dillon *et al.*
389 and Gregory *et al.* A. Number of genes found in each subpathway from Dillon's dataset,
390 with the associated false discovery rate (FDR) B. ADORA2B pathway enriched in Dillon's
391 dataset shows upregulated genes involved in ADORA2B signaling cascade leading to the
392 production of IL6 and IL10. C. Number of genes found in each subpathway from Gregory's
393 dataset, and associated FDR.

394 Discussion

395 Over-representation analysis (ORA) has become one of the standard methods for extracting
396 mechanistic information from -omics datasets. As part of the workflow, ORA matches the
397 omics data with molecular data curated in pathway databases. As a result, it gives a list of
398 pathway names in which the genes are known to be involved. Mechanistic insight must
399 then be built from a list of labels, a problem made much harder when labels lack biological

context. There are several specific cases in the literature, relating to *Leishmania*-host interaction, where this has proven to be an issue (49, 53, 54). In this work, we addressed this by creating leishmaniasis-context pathways in the Reactome database. We created four subpathways, labelled as: *Leishmania* phagocytosis, killing mechanisms, cell recruitment (pro-inflammatory response), and *Leishmania* parasite growth and survival. Inside each, we labeled the pathways according to the receptor or membrane protein directing the signaling cascade. This structure facilitates the generation of high-level mechanistic insights from low-level processes highlighted by ORA, which are sensitive to particular experimental contexts (e.g. the source of the biological sample the data was derived from).

Manual literature search is often required for in depth interpretation of the outcome of ORA for extracting biological/functional insights. However, this strategy is time consuming, prone to omissions, and certainly incompatible with unbiased exploration of novel mechanisms/functions in the data, which is the goal of -omic approaches. This is because the search is necessarily constrained to cover a small number of topics within the researcher's area of expertise, and it is unachievable to manually trawl the entirety of biological literature relating to a particular gene, microorganism or disease.

We have re-analyzed two previously published transcriptomic datasets (from *Leishmania*-infected macrophages), to provide proof-of-concept of the usefulness of context-dependent databases such as the one described in this study. Results from this secondary analysis revealed the putative participation of a signaling pathway (ADORA2B mediated anti-inflammatory cytokines production) in the parasite-mediated induction of anti-inflammatory molecules.

Although *Leishmania* infection pathways in its first version is far from representing the full current knowledge about the interaction between the parasite and the host, we have shown that our database curation has led to new mechanistic insights from existing datasets. Moreover, these findings are generated from the use of a workflow that skips particular time-consuming, problematic manual curation steps, aligning the available data interpretation tools to the nature of unbiased hypothesis generation from -omics datasets.

Materials and Methods

429 ***Leishmania* Infection Curation Process**

430 The abstraction of *Leishmania* infection into a structure of pathways and reactions fulfilling
 431 the Reactome paradigm was accomplished by the Reactome working group. This consisted
 432 of a consortium of biocurators, software developers and leishmaniasis researchers. The
 433 latter selected the mechanisms of interest. The selection was based on biological pathways
 434 known to be associated with the infectious outcome, directly or indirectly. From here,
 435 domain experts and Reactome curators worked side by side to translate the selected
 436 pathways into the Reactome data structure using the curator tool version 3.3.

437 Reactome represents, categorizes, and annotates all known entities/molecules in each
 438 reaction. Different components can interact with each other only in ways prescribed by the
 439 Reactome data-model. For instance, the representation of an individual protein in the
 440 database requires several steps. In an example, for the protein ADAM17, the UniProt ID
 441 (P78536) is retrieved, as well as the GO cellular compartment it functions, and which
 442 species this protein belongs to (e.g., *Homo sapiens*). Note that if the represented process
 443 implies the transition of the same protein from one compartment to another, different
 444 instances of this protein must be created (e.g ADAM17 [endoplasmic reticulum], ADAM17
 445 [golgi apparatus] and ADAM17 [plasma membrane]). However, all these instances still
 446 point to the same UniProt ID. On the other hand, if several proteins individually fulfil the
 447 same role in a reaction (e.g., phosphorylation), these are grouped together into a single
 448 entity called “*defined set*” (PKL2 [cytosol] and MAPK14 [cytosol] in the *defined set* PKL2,
 449 MAP14 [cytosol] that phosphorylates ADAM17 [plasma membrane]). The *defined set*
 450 entity is also specific to each cellular compartment. Therefore, each individual molecule
 451 within the *defined set* must have a compartment-specific representation. Otherwise, in the
 452 quality assurance procedure, this will come out as an error. Molecules of the same or
 453 different types can form complexes, for example ADAM17:Zn²⁺ which represents the
 454 functional form of ADAM17. Once these entities are created, the reactions in which they
 455 take part, are created. Binding is a common type of reaction in Reactome. Here, the output
 456 is a complex type entity (e.g., the interaction between sCD163 and MYH9 is represented as
 457 a binding that ends in the formation of the sCD163:MYH9 complex). If we are not at the
 458 final point of the pathway or dealing with a secondary product, the complex can participate

in subsequent reactions. In that case, the reaction from which this complex came from is indicated as the “preceding event” of the subsequent reaction.

Overall, we curated *Leishmania* infection pathways following the general structure of a signaling pathway. Namely, a ligand binding to a receptor, then the stimulated receptor effecting a downstream signaling cascade, up to the activation of effector molecules (eg. cytokines, nitric oxide, etc.). However, other pathways were conceived with different starting points. For instance, the first step of the CD163 example pathway consisted of ADAM17 activation. This begins in the endoplasmic reticulum, and its maturation process follows through the Golgi apparatus until its translocation to the plasma membrane, where its phosphorylation by kinases (either PLK2 or MAPK14), activates the cleavage reaction of CD163. It is the soluble portion of CD163, sCD163, that has been found as a regulator of the inflammatory responses in *Leishmania* infection, through the inhibition of the proliferation of T lymphocytes.

Reactome’s criteria for the acceptance of a particular molecular interaction and its supporting reference have been previously explained (3, 55). Once the reactions were successfully integrated into Reactome’s central database, we reached out to an experienced researcher in leishmaniasis, Dr. David Gregory (ORCID: 0000-0001-6534-7150) (52, 56, 57) to review the curated material on the basis of his expertise in the field (52, 57–59). Only material reviewed by an independent domain expert is allowed to be published in a Reactome release. The contributions of authors and reviewers can be directly accessed through Reactome’s search interface, for example <https://reactome.org/content/query?q=David+Gregory> shows a detailed description of credit attribution in Reactome (60). We are highly interested in further contributions from domain experts for the completion of *Leishmania* infection pathways.

Once an orderly list of reactions was created, these were transformed according to the Reactome paradigm by using the curator tool. Some reactions were created from scratch to populate a low-level pathway, while others that were present within other pathways were duplicated (or reused) in the context of *Leishmania* infection (table 1). Within a reaction, each component was re-used if it already existed as part of a different process in the

database, otherwise it was created. Reuse of existing components and reactions ensures no redundancy in the database.

Reaction details, such as input/catalyst/output molecules, reaction type, preceding reactions and experimental species, were captured during the curation process. Reactions were linked together based on preceding-following relationships to generate pathways.

Funding

This work was supported by the UK Global Challenges Research Fund CABANA grant BB/P027849/1, Wellcome Trust grant 107595/Z/15/Z to MAG, and US National Institutes of Health grant U41HG003751 (Reactome). JM was also funded by the Colombian National “Departamento Administrativo de Ciencia, Tecnología e Innovación” (COLCIENCIAS), Ph.D program, number 756-2016.

Reference

1. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S, Lomax J, Mungall C, Hitz B, Balakrishnan R, Dolan M, Wood V, Hong E, Gaudet P. 2009. AmiGO: Online access to ontology and annotation data. *Bioinformatics* 25:288–289.
2. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. 2017. KEGG: New perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res* 45:D353–D361.
3. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, Gillespie M, Haw R, Loney F, May B, Milacic M, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Weiser J, Wu G, Stein L, Hermjakob H, D’Eustachio P. 2020. The reactome pathway knowledgebase. *Nucleic Acids Res* 48:D498–D503.
4. Fabregat A, Sidiropoulos K, Viteri G, Forner O, Marin-Garcia P, Arnau V, D’Eustachio P, Stein L, Hermjakob H. 2017. Reactome pathway analysis: A high-performance in-memory approach. *BMC Bioinformatics* 18.
5. Ueno N, Wilson ME. 2012. Receptor-mediated phagocytosis of Leishmania:

- 516 implications for intracellular survival. Trends Parasitol 28:335–344.
- 517 6. Martínez-López M, Soto M, Iborra S, Sancho D. 2018. Leishmania Hijacks myeloid
518 cells for immune escape. Front Microbiol. Frontiers Media S.A.
- 519 7. Rossi M, Fasel N. 2018. How to master the host immune system? Leishmania
520 parasites have the solutions! Int Immunol 30:103–111.
- 521 8. Nylén S, Gautam S. 2010. Immunological perspectives of leishmaniasis. J Glob
522 Infect Dis 2:135.
- 523 9. Scott P, Novais FO. 2016. Cutaneous leishmaniasis: immune responses in protection
524 and pathogenesis. Nat Publ Gr.
- 525 10. Chauhan P, Shukla D, Chattopadhyay D, Saha B. 2017. Redundant and regulatory
526 roles for Toll-like receptors in *Leishmania* infection. Clin Exp Immunol 190:167–
527 186.
- 528 11. Polando R, Dixit UG, Carter CR, Jones B, Whitcomb JP, Ballhorn W, Harintho M,
529 Jerde CL, Wilson ME, McDowell MA. 2013. The roles of complement receptor 3
530 and Fcγ receptors during Leishmania phagosome maturation . J Leukoc Biol 93:921–
531 932.
- 532 12. Oghumu S, Lezama-Dávila CM, Isaac-Márquez AP, Satoskar AR. 2010. Role of
533 chemokines in regulation of immunity against leishmaniasis. Exp Parasitol 126:389–
534 396.
- 535 13. Buxbaum LU. 2013. Leishmania mexicana Infection Induces IgG to Parasite Surface
536 Glycoinositol Phospholipids that Can Induce IL-10 in Mice and Humans. PLoS Negl
537 Trop Dis 7.
- 538 14. Chu N, Thomas BN, Patel SR, Buxbaum LU. 2010. IgG1 is pathogenic in
539 Leishmania mexicana infection. J Immunol 185:6939–46.
- 540 15. Boutros M, Paricio N, Strutt DI, Mlodzik M. 1998. Dishevelled activates JNK and
541 discriminates between JNK pathways in planar polarity and wingless signaling. Cell
542 94:109–118.

- 543 16. Axelrod JD. 2001. Unipolar membrane association of Dishevelled mediates Frizzled
544 planar cell polarity signaling. *Genes Dev* 15:1182–1187.
- 545 17. Rothbächer U, Laurent MN, Deardorff MA, Klein PS, Cho KWY, Fraser SE. 2000.
546 Dishevelled phosphorylation, subcellular localization and multimerization regulate
547 its role in early embryogenesis. *EMBO J* 19:1010–1022.
- 548 18. Wong HC, Mao J, Nguyen JT, Srinivas S, Zhang W, Liu B, Li L, Wu D, Zheng J.
549 2000. Structural basis of the recognition of the Dishevelled DEP domain in the Wnt
550 signaling pathway. *Nat Struct Biol* 7:1178–1184.
- 551 19. Witzel S, Zimyanin V, Carreira-Barbosa F, Tada M, Heisenberg CP. 2006. Wnt11
552 controls cell contact persistence by local accumulation of Frizzled 7 at the plasma
553 membrane. *J Cell Biol* 175:791–802.
- 554 20. Blumenthal A, Ehlers S, Lauber J, Buer J, Lange C, Goldmann T, Heine H, Brandt
555 E, Reiling N. 2006. The Wingless homolog WNT5A and its receptor Frizzled-5
556 regulate inflammatory responses of human mononuclear cells induced by microbial
557 stimulation. *Blood* 108:965–973.
- 558 21. Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G. 2008. Wnt5A/CaMKII
559 signaling contributes to the inflammatory response of macrophages and is a target for
560 the antiinflammatory action of activated protein C and interleukin-10. *Arterioscler
561 Thromb Vasc Biol* 28:504–510.
- 562 22. Ljungberg JK, Kling JC, Tran TT, Blumenthal A. 2019. Functions of the WNT
563 Signaling Network in Shaping Host Responses to Infection. *Front Immunol* 10:2521.
- 564 23. Chakraborty A, Kurati SP, Mahata SK, Sundar S, Roy S, Sen M. 2017. Wnt5a
565 Signaling Promotes Host Defense against *Leishmania donovani* Infection . *J
566 Immunol* 199:992–1002.
- 567 24. Shao Y, Zheng Q, Wang W, Xin N, Song X, Zhao C. 2016. Biological functions of
568 macrophage-derived Wnt5a, and its roles in human diseases. *Oncotarget*. Impact
569 Journals LLC.
- 570 25. Atri C, Guerfali FZ, Laouini D. 2018. Role of human macrophage polarization in

inflammation during infectious diseases. *Int J Mol Sci*. MDPI AG.

26. Coutinho-Silva R, Ojcius DM. 2012. Role of extracellular nucleotides in the immune response against intracellular bacteria and protozoan parasites. *Microbes Infect* 14:1271–1277.

27. Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, White MR, Dinarello CA, Apte RN. 2011. IL-1 α and IL-1 β Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation. *J Immunol* 187:4835–4843.

28. Cekic C, Linden J. 2016. Purinergic regulation of the immune system. *Nat Rev Immunol* 16:177–92.

29. Maspi N, Abdoli A, Ghaffarifar F. 2016. Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review. *Pathog Glob Health*. Taylor and Francis Ltd.

30. Silva RLL, Santos MB, Almeida PLS, Barros TS, Magalhães L, Cazzaniga RA, Souza PRM, Luz NF, França-Costa J, Borges VM, Lima-Junior DS, Lipscomb MW, Duthie MS, Reed SG, Almeida RP, Jesus AR. 2017. sCD163 levels as a biomarker of disease severity in leprosy and visceral leishmaniasis. *PLoS Negl Trop Dis* 11:e0005486.

31. Roy S, Mukhopadhyay D, Mukherjee S, Moulik S, Chatterji S, Brahme N, Pramanik N, Goswami RP, Saha B, Chatterjee M. 2018. An IL-10 dominant polarization of monocytes is a feature of Indian Visceral Leishmaniasis. *Parasite Immunol* 40:e12535.

32. Moreira PRR, Fernando FS, Montassier HJ, André MR, de Oliveira Vasconcelos R. 2016. Polarized M2 macrophages in dogs with visceral leishmaniasis. *Vet Parasitol* 226:69–73.

33. Högger P, Sorg C. 2001. Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation. *Biochem Biophys Res Commun* 288:841–3.

34. Timmermann M, Buck F, Sorg C, Högger P. 2004. Interaction of soluble CD163 with activated T lymphocytes involves its association with non-muscle myosin heavy chain type A. *Immunol Cell Biol* 82:479–487.

- 599 35. Etzerodt A, Moestrup SK. 2013. CD163 and inflammation: biological, diagnostic,
600 and therapeutic aspects. *Antioxid Redox Signal* 18:2352–63.
- 601 36. Etzerodt A, Rasmussen MR, Svendsen P, Chalaris A, Schwarz J, Galea I, Møller HJ,
602 Moestrup SK. 2014. Structural basis for inflammation-driven shedding of CD163
603 ectodomain and tumor necrosis factor- α in macrophages. *J Biol Chem* 289:778–788.
- 604 37. Sulahian TH, Högger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, Droste A,
605 Stehling M, Wallace PK, Morganelli PM, Guyre PM. 2000. Human monocytes
606 express CD163, which is upregulated by IL-10 and identical to p155. *Cytokine*
607 12:1312–21.
- 608 38. Högger P, Erpenstein U, Rohdewald P, Sorg C. 1998. Biochemical characterization
609 of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its
610 application as model system for ranking glucocorticoid potency. *Pharm Res* 15:296–
611 302.
- 612 39. Buechler C, Ritter M, Orsó E, Langmann T, Klucken J, Schmitz G. 2000. Regulation
613 of scavenger receptor CD163 expression in human monocytes and macrophages by
614 pro- and antiinflammatory stimuli. *J Leukoc Biol* 67:97–103.
- 615 40. Wenzel I, Roth J, Sorg C. 1996. Identification of a novel surface molecule, RM3/1,
616 that contributes to the adhesion of glucocorticoid-induced human monocytes to
617 endothelial cells. *Eur J Immunol* 26:2758–2763.
- 618 41. Vogelpoel LTC, Hansen IS, Rispens T, Muller FJM, Van Capel TMM, Turina MC,
619 Vos JB, Baeten DLP, Kapsenberg ML, De Jong EC, Den Dunnen J. 2014. Fc gamma
620 receptor-TLR cross-talk elicits pro-inflammatory cytokine production by human M2
621 macrophages. *Nat Commun* 5.
- 622 42. Asadullah K, Sterry W, Volk HD. 2003. Interleukin-10 therapy - Review of a new
623 approach. *Pharmacol Rev. American Society for Pharmacology and Experimental*
624 *Therapy*.
- 625 43. Vijayamahantesh, Amit A, Kumar S, Dikhit MR, Jha PK, Singh AK, Sinha KK,
626 Pandey K, Das VNR, Das P, Bimal S. 2016. Up regulation of A2B adenosine

receptor on monocytes are crucially required for immune pathogenicity in Indian patients exposed to *Leishmania donovani*. *Cytokine* 79:38–44.

44. de Almeida Marques-da-Silva E, de Oliveira JC, Figueiredo AB, de Souza Lima Júnior D, Carneiro CM, Rangel Fietto JL, Crocco Afonso LC. 2008. Extracellular nucleotide metabolism in *Leishmania*: influence of adenosine in the establishment of infection. *Microbes Infect* 10:850–857.

45. Lima MHF, Sacramento LA, Quirino GFS, Ferreira MD, Benevides L, Santana AKM, Cunha FQ, Almeida RP, Silva JS, Carregaro V. 2017. *Leishmania infantum* parasites subvert the host inflammatory response through the adenosine A2A receptor to promote the establishment of infection. *Front Immunol* 8:815.

46. Figueiredo AB de, Souza-Testasica MC, Afonso LCC. 2016. Purinergic signaling and infection by *Leishmania*: A new approach to evasion of the immune response [figure presented]. *Biomed J. Elsevier B.V.*

47. Sun WC, Moore JN, Hurley DJ, Vandenplas ML, Linden J, Cao Z, Murray TF. 2008. Adenosine A2A receptor agonists inhibit lipopolysaccharide-induced production of tumor necrosis factor- α by equine monocytes. *Vet Immunol Immunopathol* 121:91–100.

48. Lucas M, Zhang X, Prasanna V, Mosser DM. 2005. ERK Activation Following Macrophage Fc γ R Ligation Leads to Chromatin Modifications at the IL-10 Locus. *J Immunol* 175:469–477.

49. Dillon LAL, Suresh R, Okrah K, Corrada Bravo H, Mosser DM, El-Sayed NM. 2015. Simultaneous transcriptional profiling of *Leishmania major* and its murine macrophage host cell reveals insights into host-pathogen interactions. *BMC Genomics* 16:1108.

50. Camera M, Giesen PLA, Fallon J, Aufiero BM, Taubman M, Tremoli E, Nemerson Y. 1999. Cooperation Between VEGF and TNF- α Is Necessary for Exposure of Active Tissue Factor on the Surface of Human Endothelial Cells. *Arterioscler Thromb Vasc Biol* 19:531–537.

51. Mechtcheriakova D, Schabbauer, I. Mechtcheriakova D, Schabbauer G, Lucerna M, Clauss M, Martin R De, Binder, R. B, HOFER E. 2001. Specificity, diversity and convergence in V and T signaling events leading to tissue factor up regulation via E in endothelial cells. FJ 15:230–242. G, Lucerna M, Clauss M, Martin R De, Binder, R. B, HOFER E. 2001. Specificity, diversity, and convergence in VEGF and TNF- α signaling events leading to tissue factor up regulation via EGR-1 in endothelial cells. FASEB J 15:230–242.
52. Gregory DJ, Sladek R, Olivier M, Matlashewski G. 2008. Comparison of the effects of Leishmania major or Leishmania donovani infection on macrophage gene expression. Infect Immun 76:1186–1192.
53. Fernandes MC, Dillon LAL, Belew AT, Bravo HC, Mosser DM, El-Sayed NM. 2016. Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. MBio 7:e00027-16.
54. Maretti-Mira AC, Bittner J, Oliveira-Neto MP, Liu M, Kang D, Li H, Pirmez C, Craft N. 2012. Transcriptome Patterns from Primary Cutaneous Leishmania braziliensis Infections Associate with Eventual Development of Mucosal Disease in Humans. PLoS Negl Trop Dis 6:e1816.
55. Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B, Korninger F, May B, Milacic M, Roca CD, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Viteri G, Weiser J, Wu G, Stein L, Hermjakob H, D'Eustachio P. 2018. The Reactome Pathway Knowledgebase. Nucleic Acids Res 46:D649–D655.
56. Olivier M, Gregory DJ, Forget G. 2005. Subversion mechanisms by which Leishmania parasites can escape the host immune response: A signaling point of view. Clin Microbiol Rev.
57. Gregory DJ, Godbout M, Contreras I, Forget G, Olivier M. 2008. A novel form of NF- κ B is induced by Leishmania infection: Involvement in macrophage gene expression. Eur J Immunol 38:1071–1081.
58. Contreras I, Gómez MA, Nguyen O, Shio MT, McMaster RW, Olivier M. 2010.

Leishmania-induced inactivation of the macrophage transcription factor AP-1 is mediated by the parasite metalloprotease GP63. PLoS Pathog 6:e1001148.

59. DA V, DJ G, RN K, D Z, AT B, NM E-S, MA G. 2020. Macrophage metallothioneins participate in the antileishmanial activity of antimonials.
60. Viteri G, Matthews L, Varusai T, Gillespie M, Milacic M, Cook J, Weiser J, Shorser S, Sidiropoulos K, Fabregat A, Haw R, Wu G, Stein L, D'Eustachio P, Hermjakob H. 2019. Reactome and ORCID-fine-grained credit attribution for community curation. Database (Oxford) 2019.

Supplementary material description

S1: It is an excel file with two tabs. The first one contains the gene input from the paper by Dillon *et al.* (49). The second one contains the output of applying ORA to that gene list.

S2: It is an excel file with two tabs. The first one contains the gene input from the paper by Gregory *et al.* (52). The second one contains the output of applying ORA to that gene list.

Figure 1: Textbook-style diagram representing the top-level pathway “*Leishmania* infection”. The major steps occurring in the dermis were compartmentalized into four categories: phagocytosis, killing mechanisms, cell recruitment, and *Leishmania* parasite growth and survival. On the webpage (<https://reactome.org/PathwayBrowser/#/R-HSA-9658195>), the magenta rectangular labels are interactive and take the user to the content of each subpathway.

- Leishmania infection
 - Parasite infection
 - Leishmania phagocytosis
 - FCGR3A-mediated phagocytosis
 - Killing mechanisms
 - WNT5:FZD7-mediated leishmania damping
 - Cell recruitment (pro-inflammatory response)
 - Purinergic signaling in leishmaniasis infection
 - Leishmania parasite growth and survival
 - Anti-inflammatory response favouring Leishmania parasite infection
 - CD163 mediating an anti-inflammatory response
 - FCGR3A-mediated IL10 synthesis
 - ADORA2B mediated anti-inflammatory cytokines production
 - LTC4-CYSLTR mediated IL4 production

Figure 2: Hierarchical structure of the *Leishmania* infection pathway showing the four sub-pathways and their contents. Each indentation introduces a new subpathway; as an example, “parasite infection” is the parent pathway for the subpathway “*Leishmania* phagocytosis”, which, to date only contains FCGR3A-mediated phagocytosis.

B.

Figure 3: Standard graphical representation of pathways in Reactome. **A.** Fragment of the diagram for FCGR3A-mediated phagocytosis. It shows the reactions corresponding to the parasite opsonization process by the IgG. Parasitic components are highlighted in red. **B.** CD163 mediating an anti-inflammatory response. Each diagram shows the participating entities in the granularity of chemical compounds (green ovals), proteins (green rectangles), complexes (blue rectangles) and sets (blue rectangles with a double border). The arrangement

of the entities in the reactions can be easily followed on the web page, by clicking on the arrows that connect adjacent steps.

- A.
- Leishmania infection (45/403) FDR: 9.97E-1
 - Parasite infection (9/157) FDR: 10E-1
 - Leishmania phagocytosis (9/157) FDR: 10E-1
 - FCGR3A-mediated phagocytosis (9/157) FDR: 10E-1
 - Killing mechanisms
 - Cell recruitment (pro-inflammatory response) (6/48) FDR: 7.9E-1
 - Purinergic signaling in leishmaniasis infection (6/48) FDR: 7.9E-1
 - Leishmania parasite growth and survival (34/297) FDR: 9.87E-1
 - Anti-inflammatory response favouring Leishmania parasite infection (34/297) FDR: 9.87E-1
 - CD163 mediating an anti-inflammatory response (4/14) FDR: 7.72E-1
 - FCGR3A-mediated IL10 synthesis (12/141) FDR: 9.95E-1
 - ADORA2B mediated anti-inflammatory cytokines production (20/159) FDR: 8.98E-1
 - LTC4-CYSLTR mediated IL4 production (4/14) FDR: 7.72E-1

Figure 4: Results of applying ORA in Reactome, on the datasets generated by Dillon *et al.* and Gregory *et al.* A. Number of genes found in each subpathway from Dillon's dataset, with the associated false discovery rate (FDR) B. ADORA2B pathway enriched in Dillon's dataset shows upregulated genes involved in ADORA2B signaling cascade leading to the production of IL6 and IL10. C. Number of genes found in each subpathway from Gregory's dataset, and associated FDR.